



OMNIGRAF™

Kidney



The first and only non-invasive panel that combines genetic biomarker tests for the earliest and most accurate view of kidney transplant rejection




One Powerful Panel, Two Targeted Biomarkers

OmniGraf™ is the first and only non-invasive test panel that combines novel genetic biomarkers for the earliest and most accurate view of kidney transplant rejection.


Combining gene expression profiling with donor-derived cell-free DNA for increased precision and accuracy, **OmniGraf** delivers clinically-actionable data on rejection status — empowering clinicians to provide the best possible long-term outcomes.



OmniGraf: The Power of One



One All-Inclusive
Sample Collection Kit



One 6ml
Routine Blood Draw




One Overnight Shipment



One Easy-to-Interpret
Longitudinal Report

1. 89% Positive Predictive Value when both TruGraf and TRAC assays return positive results.



OmniGraf is the combination of two complementary biomarker assays, TruGraf and TRAC, that each offer a discrete view of the transplant rejection process, providing comprehensive unparalleled insight into the patient's allograft health.

Requiring only a routine 6ml blood draw, OmniGraf results are returned within 4 days, facilitating a rapid clinical response.



TRUGRAF®

Microfluidic gene expression classification of the 120 specific genes that express during subclinical acute rejection.


Learn more at
transplantgenomics.com/trugraf-kidney




VIRACOR TRAC®

Next-generation sequencing of donor-derived cell-free DNA, analyzing the whole genome (~100,000+ SNPs) for evaluating clinical acute rejection.

Learn more at
transplantgenomics.com/trac-kidney





One Easy-to-Interpret Longitudinal Report

The OmniGraf results report displays both the TRAC donor-derived cell-free DNA value as well as the TruGraf TX / Not-TX values longitudinally, helping clinicians understand how each patient’s unique transplant health journey unfolds over time.



Patient Care and Coverage

Transplant Genomics is committed to providing testing ordered and deemed medically necessary by a physician, regardless of our network status with private insurances. Our Patient Financial Assistance program is designed to tailor solutions for uninsured or underinsured patients based on individual circumstances. In certain circumstances — specifically depending upon the patient’s financial status and the applicable law — we may adjust some or all laboratory charges if the patient cannot afford to pay for their testing.

In all cases, our team is here to help providers and patients navigate billing, preauthorization, or reimbursement questions. We can be reached at 1-844-878-4723.



“Blood-based biomarkers may allow less invasive, more frequent monitoring of kidney transplant recipients for subclinical rejection. Donor derived cfDNA was significantly better at detecting subclinical antibody mediated rejection when compared with the gene expression profile, and conversely the gene expression profile was significantly better at detecting subclinical acute cellular rejection. When both gene expression profile and donor derived cfDNA are negative or positive, their NPV or PPV is higher than either test alone.”

“Combining Blood Gene Expression and Cell-Free DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients”
Clinical Journal of the American Society of Nephrology, October 2021

Park S, MD; Guo K; Heilman R, MD; Poggio E, MD; Taber D, PharmD, MS; Marsh C, MD; Kurian S, PhD; Kleiwoecker S, PhD; Weems J, PhD; Holman J, MD, PhD; Zhao L, PhD; Sinha R, PhD; Brietigam S, BA, CCRC, CAPM; Rebello C; Abecassis M, MD, MBA; Friedewald J, MD



Learn more at transplantgenomics.com/omnigraf



@EurofinsTGI



Transplant Genomics

© 2021 Eurofins. OmniGraf is a trademark and Viracor TRAC and TruGraf are registered trademarks of Eurofins. All rights reserved.

005-01-001 v2 / Oct 2021